
27/02/2025
💊 More Zepbound Options: A Step Forward, But Gaps Remain 💊
Lilly announced earlier this week new, lower-priced, 7.5 mg and 10 mg dose vials of Zepbound (tirzepatide)—a move that could help those whose insurance do not cover the medication or those seeking alternatives to compounded versions.
While this expands access, cost and coverage barriers still leave many without treatment. We need to work towards ensuring that everyone has access to the comprehensive obesity care.
🔗 Read more on what this means for patients and what still needs to change on our blog page:
https://www.anisemedical.com/blog/lilly-expands-zepbound-options-a-step-in-the-right-direction-but-more-work-to-be-done